Nevada Clinical Trials Report — April 2026

For Nevadans considering participation in clinical research, April 2026 brings a mix of urgent opportunities and new avenues for exploration. A total of 30 clinical trials across the state are slated to close their enrollment within the next 90 days. This means time is running out to join these studies, particularly for the 3 trials among them that are actively seeking healthy volunteers. If you've been contemplating contributing to medical science without a specific health condition, now is the moment to act before these opportunities vanish.

Patients managing certain conditions also face impending deadlines to join research. Trials focused on neurological disorders, various cancers, and chronic pain are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Major depressive disorder
• Amyotrophic lateral sclerosis (ALS)
• Behavioral variant frontotemporal dementia (bvFTD)
• Anatomic stage III breast cancer AJCC v8
• Asthma
• Attention-deficit/hyperactivity disorder (ADHD)
• Anatomic stage II breast cancer AJCC v8
• Benign prostatic hyperplasia (BPH)
• Bladder pain syndrome
• Breast cancer

Spotlight on New Research: Chronic Pain, Diabetes, and Rare Skin Conditions

This month, Nevada welcomes 3 new clinical trials, offering fresh opportunities for residents to engage with cutting-edge research. While this number is lower than the 11 new trials that opened in March 2026, these new studies address significant health challenges and are sponsored by notable institutions and pharmaceutical companies.

• The University of Sydney is sponsoring NCT07532070, a comparative effectiveness study titled "SLEEPFIT TRIAL." This trial is investigating which lifestyle approach—exercise, cognitive behavioral therapy, or a combination—is most effective for individuals experiencing chronic musculoskeletal pain, such as low back pain or hip/knee osteoarthritis, who also suffer from poor sleep. This behavioral study aims to enroll 384 participants in a 12-month home-based program, offering a non-pharmacological approach to managing complex conditions.
• Housey Healthcare ULC is launching NCT07546929, a Phase 2 dose-ranging study evaluating the safety and efficacy of HP-211 in patients with Type 2 Diabetes. This drug trial seeks 300 participants to explore a new potential treatment designed to help control blood sugar levels. Understanding how new compounds interact with the body's insulin production is crucial for developing improved diabetes management strategies.
• Palvella Therapeutics, Inc. is initiating NCT07552077, a Phase 2, baseline-controlled study. This research will evaluate the safety and effectiveness of PTX-022 (Sirolimus) Topical Gel 3.9% for the treatment of angiokeratomas, a rare skin condition. This study is designed for 15 participants, focusing on a targeted approach to a specific dermatological need.

Nevada's Research Landscape: Geographic Reach and Participation

Nevada currently hosts a robust research environment with 541 clinical trials actively recruiting across 14 cities and 396 research sites. This broad distribution ensures that opportunities are available beyond major metropolitan areas, making participation more accessible for residents statewide.

This month's new trials are geographically concentrated, with 2 opening in Las Vegas and 1 in San Antonio. While Las Vegas remains a hub for clinical research, the presence of trials in other locations highlights the expanding reach of medical studies across the state.

The new studies launched this month are focused on a diverse set of conditions, including:

• Angiokeratomas
• Insomnia
• Low back pain
• Osteoarthritis of the knee and hip
• Type 2 diabetes

The types of interventions being studied are varied, with 2 new trials being drug-based and 1 focusing on behavioral interventions. This blend reflects a comprehensive approach to addressing different aspects of health and wellness.

Who Can Participate? Healthy Volunteers and Specific Demographics

Participation in clinical trials is open to a wide range of individuals, and this month's new trials reflect that diversity. All 3 new trials include older adults, ensuring that senior populations have ample opportunities to contribute to medical science. Additionally, 1 of the new studies is open to children, providing avenues for younger participants to engage in research.

For individuals without a specific medical condition, opportunities to contribute are available. While none of the 3 new trials launched this month are specifically seeking healthy volunteers, there are still significant options statewide. A total of 39 clinical trials across Nevada are currently recruiting healthy participants. Coupled with the 3 closing-soon trials that accept healthy volunteers, this provides numerous avenues for those interested in supporting medical research and advancing public health.

Academic institutions and industry sponsors are both driving research efforts in Nevada. The University of Sydney, an academic institution, is sponsoring one of the notable new trials. Industry sponsors, including Housey Healthcare ULC and Palvella Therapeutics, Inc., are leading the other 2 new studies, demonstrating a strong collaboration between academic research and pharmaceutical development in the state.

As we move through April, Nevadans are encouraged to explore these diverse opportunities, whether seeking treatment for a specific condition or contributing as a healthy volunteer, to help shape the future of medicine.